227 related articles for article (PubMed ID: 17455042)
1. Efficacy of an oral contraceptive containing drospirenone in the treatment of women with polycystic ovary syndrome.
Pehlivanov B; Mitkov M
Eur J Contracept Reprod Health Care; 2007 Mar; 12(1):30-5. PubMed ID: 17455042
[TBL] [Abstract][Full Text] [Related]
2. [Use of yasmin in the treatment of women with polycystic ovary syndrome].
Pekhlivanov B; Mitkov M; Ivancheva Kh; Amaliev I
Akush Ginekol (Sofiia); 2006; 45(3):25-9. PubMed ID: 16889184
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of a new oral contraceptive containing drospirenone and ethinyl estradiol in the long-term treatment of hirsutism.
Batukan C; Muderris II
Fertil Steril; 2006 Feb; 85(2):436-40. PubMed ID: 16595223
[TBL] [Abstract][Full Text] [Related]
4. Effects of metformin and ethinyl estradiol-cyproterone acetate on clinical, endocrine and metabolic factors in women with polycystic ovary syndrome.
Wu J; Zhu Y; Jiang Y; Cao Y
Gynecol Endocrinol; 2008 Jul; 24(7):392-8. PubMed ID: 18608522
[TBL] [Abstract][Full Text] [Related]
5. The effects of oral contraceptives including low-dose estrogen and drospirenone on the concentration of leptin and ghrelin in polycystic ovary syndrome.
Sağsöz N; Orbak Z; Noyan V; Yücel A; Uçar B; Yildiz L
Fertil Steril; 2009 Aug; 92(2):660-6. PubMed ID: 18973889
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of effects of an oral contraceptive containing ethinylestradiol combined with drospirenone on adrenal steroidogenesis in hyperandrogenic women with polycystic ovary syndrome.
De Leo V; Morgante G; Piomboni P; Musacchio MC; Petraglia F; Cianci A
Fertil Steril; 2007 Jul; 88(1):113-7. PubMed ID: 17418832
[TBL] [Abstract][Full Text] [Related]
7. Combined use of metformin and ethinyl estradiol-cyproterone acetate in polycystic ovary syndrome.
Mitkov M; Pehlivanov B; Terzieva D
Eur J Obstet Gynecol Reprod Biol; 2005 Feb; 118(2):209-13. PubMed ID: 15653205
[TBL] [Abstract][Full Text] [Related]
8. A prospective randomized trial comparing low-dose ethinyl estradiol and drospirenone 24/4 combined oral contraceptive vs. ethinyl estradiol and drospirenone 21/7 combined oral contraceptive in the treatment of hirsutism.
Oner G; Muderris II
Contraception; 2011 Nov; 84(5):508-11. PubMed ID: 22018126
[TBL] [Abstract][Full Text] [Related]
9. Effect of oral contraceptive containing ethinyl estradiol combined with drospirenone vs. desogestrel on clinical and biochemical parameters in patients with polycystic ovary syndrome.
Kriplani A; Periyasamy AJ; Agarwal N; Kulshrestha V; Kumar A; Ammini AC
Contraception; 2010 Aug; 82(2):139-46. PubMed ID: 20654754
[TBL] [Abstract][Full Text] [Related]
10. Comparative study of the therapeutic effects of oral contraceptive pills containing desogestrel, cyproterone acetate, and drospirenone in patients with polycystic ovary syndrome.
Bhattacharya SM; Jha A
Fertil Steril; 2012 Oct; 98(4):1053-9. PubMed ID: 22795636
[TBL] [Abstract][Full Text] [Related]
11. Determining the time androgens and sex hormone-binding globulin take to return to baseline after discontinuation of oral contraceptives in women with polycystic ovary syndrome: a prospective study.
Sánchez LA; Pérez M; Centeno I; David M; Kahi D; Gutierrez E
Fertil Steril; 2007 Mar; 87(3):712-4. PubMed ID: 17118366
[TBL] [Abstract][Full Text] [Related]
12. Metformin versus rosiglitazone in the treatment of polycystic ovary syndrome.
Mitkov M; Pehlivanov B; Terzieva D
Eur J Obstet Gynecol Reprod Biol; 2006 May; 126(1):93-8. PubMed ID: 16360262
[TBL] [Abstract][Full Text] [Related]
13. Effect of oral contraceptives on markers of hyperandrogenism and SHBG in women with polycystic ovary syndrome.
De Leo V; Di Sabatino A; Musacchio MC; Morgante G; Scolaro V; Cianci A; Petraglia F
Contraception; 2010 Sep; 82(3):276-80. PubMed ID: 20705157
[TBL] [Abstract][Full Text] [Related]
14. Oral contraceptive plus antiandrogen therapy and cardiometabolic risk in polycystic ovary syndrome.
Harmanci A; Cinar N; Bayraktar M; Yildiz BO
Clin Endocrinol (Oxf); 2013 Jan; 78(1):120-5. PubMed ID: 22702394
[TBL] [Abstract][Full Text] [Related]
15. Effects of ethinyl estradiol and desogestrel on clinical and metabolic parameters in Indian patients with polycystic ovary syndrome.
Bhattacharya SM; Ghosh M; Basu R
J Obstet Gynaecol Res; 2012 Jan; 38(1):285-90. PubMed ID: 22070369
[TBL] [Abstract][Full Text] [Related]
16. Obesity, weight loss, and the polycystic ovary syndrome: effect of treatment with diet and orlistat for 24 weeks on insulin resistance and androgen levels.
Panidis D; Farmakiotis D; Rousso D; Kourtis A; Katsikis I; Krassas G
Fertil Steril; 2008 Apr; 89(4):899-906. PubMed ID: 17980364
[TBL] [Abstract][Full Text] [Related]
17. Endocrinological, metabolic and clinical features of treatment with oral contraceptive formulation containing ethinylestradiol plus chlormadinone acetate in nonobese women with polycystic ovary syndrome.
Uras R; Orrù M; Pani F; Marotto MF; Pilloni M; Guerriero S; Etzi R; Zedda P; Sorge R; Lello S; Melis GB; Paoletti AM
Contraception; 2010 Aug; 82(2):131-8. PubMed ID: 20654753
[TBL] [Abstract][Full Text] [Related]
18. Treatment of hirsutism with combined pill containing drospirenone.
Gregoriou O; Papadias K; Konidaris S; Bakalianou K; Salakos N; Vrachnis N; Creatsas G
Gynecol Endocrinol; 2008 Apr; 24(4):220-3. PubMed ID: 18382909
[TBL] [Abstract][Full Text] [Related]
19. [Individualization of low-dose oral contraceptives. Pharmacological principles and practical indications for oral contraceptives].
Cianci A; De Leo V
Minerva Ginecol; 2007 Aug; 59(4):415-25. PubMed ID: 17923832
[TBL] [Abstract][Full Text] [Related]
20. The impact of oral contraceptives and metformin on anti-Müllerian hormone serum levels in women with polycystic ovary syndrome and biochemical hyperandrogenemia.
Panidis D; Georgopoulos NA; Piouka A; Katsikis I; Saltamavros AD; Decavalas G; Diamanti-Kandarakis E
Gynecol Endocrinol; 2011 Aug; 27(8):587-92. PubMed ID: 20836726
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]